Abatacept and Ruxolitinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Ruxolitinib
Abatacept
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Ruxolitinib (Jakafi, Opzelura) and abatacept (Orencia) both calm down parts of your immune system. Ruxolitinib blocks certain immune signals, and abatacept dials down immune cells too. When you take them together, your immune defenses can be lowered more than intended, which can make it easier to catch infections or make an infection harder to fight off.
Because using these two together hasn't been well studied, experts generally advise against combining them. The good news is that your care team can look at your full picture and pick a safer plan. Please don't stop or change anything on your own, just check in with your doctor or pharmacist so they can guide you.
Effect: Additive immunosuppression with increased infection risk when combining ruxolitinib (a JAK1/2 inhibitor) with abatacept (a selective T-cell costimulation modulator). Neither agent is a prodrug; this is a pharmacodynamic, not metabolic, concern.
- Direction: Overlapping immunosuppressive activity heightens susceptibility to serious infections.
- Mechanism: Unknown/unspecified; presumed additive PD effect on immune function.
- Evidence: Theoretical; insufficient data on safety and efficacy of concurrent use.
- Onset: Unspecified.
- Management: Concurrent therapy is not recommended. If both are being considered, defer to the prescriber; monitor closely for signs of infection.
What happens
An increased risk of infection
Interaction Deep Dive
Data are lacking to assess whether the combination of abatacept and janus kinase inhibitors is safe and effective. As a result, using these agents together is not advised1.
Why it happens (mechanism)
Unknown
How to manage this interaction
Both medicines quiet the immune system, so using them together can raise your chance of infection. Guidance on file is that this combination is not recommended.
- Keep taking your medications as prescribed unless your care team tells you otherwise. Do not stop either drug on your own.
- Ask your prescriber or pharmacist whether both are truly needed together, or whether an alternative is a better fit for you.
- Watch for signs of infection (fever, chills, sore throat, cough, burning with urination, redness or drainage) and report them promptly.
- Your team may monitor you more closely if the combination is unavoidable.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Abatacept and Ruxolitinib together?
Ruxolitinib and abatacept both suppress the immune system, so combining them is generally not recommended because of a higher infection risk. Keep taking what you're prescribed and talk with your doctor or pharmacist before making any changes. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Abatacept and Ruxolitinib interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Abatacept and Ruxolitinib interaction managed?
Both medicines quiet the immune system, so using them together can raise your chance of infection. Guidance on file is that this combination is not recommended. Keep taking your medications as prescribed unless your care team tells you otherwise. Do not stop either drug on your own. Ask your prescriber or pharmacist whether both are truly needed together, or whether an alternative is a better fit… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Abatacept or Ruxolitinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ORENCIA(R) intravenous, subcutaneous injection, abatacept intravenous, subcutaneous injection. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Ruxolitinib
Keep reading about Abatacept
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist